Grant C. retweeted
At #EuroPCR 2024, global experts discussed complex procedures performed with #DynamX® Coronary Bioadaptor System & how restoring vessel viability leads to clinical benefits.
bit.ly/4d1WE8N
CE marked. Not for sale in the U.S.
PMN 1938 REV A
Grant C. retweeted
ICYMI: Watch @Antocol17, Stefan Verheye, M.D., & @DFCapodanno share perspectives on #BIOADAPTOR RCT 2-year outcomes at #EuroPCR 2024 here: bit.ly/3XVO7ji
CE marked. Not for sale in the U.S.
#CardioTwitter
PMN 1939 REV A
Grant C. retweeted
Congratulations Prof. Letilović, Prof. Starcevic, Dr. Richter, and Chief Nurse Mrs. Posilovic and her team at Clinical Hospital Merkur Zagreb for advancing patient care by completing their first bioadaptive angioplasty cases with #DynamX.
Learn more: elixirmedical.com/technologi…
Grant C. retweeted
.@ElixirMed receives FDA Breakthrough Device Designation for DynamX system: hubs.ly/Q02Cf7_G0
Grant C. retweeted
ICYMI: At #EuroPCR, we shared late-breaking 2-year data showing #DynamX® Coronary Bioadaptor’s significant clinical advantages vs. DES.
Learn more about the results: elixirmedical.com/clinical-e…
CE marked. Not for sale in the U.S.
#Bioadaptor #Medtech #Innovation #CardioTwitter
Grant C. retweeted
Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT dlvr.it/T7Wbkm
Grant C. retweeted
The first-time application of a triple-drug, site-specific antithrombotic therapy on a stent platform was safe and effective for managing thrombotic and bleeding risk after PCI #TCT2023 @TCTConference @CRFHeart #Cardiotwitter
Read more 👇
healio.com/news/cardiac-vasc…
Grant C. retweeted
#BreakingNews: Our RCT data comparing the novel bioadaptor technology against a contemporary DES at 12 months has just been published in eClinicalMedicine, part of @TheLancet!
Read more: thelancet.com/journals/eclin…
PMN 1699 REV B
Grant C. retweeted
Are you at #TCT2023? Visit us at booth 246 to learn more about our innovations to elevate the standard of care for patients with #CAD.
#Medtech #Innovation #CardioTwitter
PMN 1662 REV A
Grant C. retweeted
How do you transform a market that hasn’t seen innovation in 20+ years?
You keep going when others have quit. CEO Motasim Sirhan discusses Elixir’s journey to develop a portfolio designed to meaningfully impact PCI patients’ lives.
Read more
PMN 1654 REV A
Grant C. retweeted
Heading to San Francisco for #TCT2023? Learn about Elixir and innovative #cardiovascular technologies.
Find us at booth 246 and explore our presentations this week!
#CardioTwitter #Innovation
PMN 1658 REV A
Grant C. retweeted
The #PerfectPCI story continues……@AGIKinterv
We’re pleased to announce our 8 presentations, including new data on our latest innovation DESyne® BDS Plus, at #TCT2023.
Meet us at booth 115 and learn how we’re transforming care for patients with heart and #VascularDisease.
elixirmedical.com/elixir-med…
Grant C. retweeted
We’re pleased to announce our 8 presentations, including new data on our latest innovation DESyne® BDS Plus, at #TCT2023.
Meet us at booth 115 and learn how we’re transforming care for patients with heart and #VascularDisease.
elixirmedical.com/elixir-med…
Grant C. retweeted
Did you hear? We have submitted our application for Japan’s PMDA approval for our DynamX Bioadaptor technology!
Learn more here:
elixirmedical.com/elixir-med…
Grant C. retweeted
Stefan Verheye, M.D., talks about ‘never before seen’ results achieved through the BIOADAPTOR RCT 12-month clinical data comparing the DynamX Bioadaptor to Resolute Onyx DES.
radcliffecardiology.com/vide…
#Cardiology #cardiovascular
Grant C. retweeted
You know it, you tell the story!
The Bears are back-to-back National Champions!
#GoBears
Grant C. retweeted
@ElixirMed is proudly aligned with @goredforwomen and is committed to transforming care of patients with heart and vascular disease through innovation.
See @goredforwomen to learn more & find ways to support the @American_Heart initiative.
#WearRedDay #HeartMonth
Grant C. retweeted
𝘉𝘈𝘊𝘒 2 𝘉𝘈𝘊𝘒 𝙉𝘼𝙏𝙄𝙊𝙉𝘼𝙇 𝘾𝙃𝘼𝙈𝙋𝙄𝙊𝙉𝙎
#GoBears 🐻🏆



























